VRTX Q3 2023 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.5B+6.4% YoY

Gross Profit

$2.2B87.2% margin

Operating Income

$1.0B41.8% margin

Net Income

$1.0B41.7% margin

EPS (Diluted)

$3.97

QoQ Revenue Growth

-0.4%

Cash Flow

Operating Cash Flow

$1.3B

Free Cash Flow

$1.2B

Stock-Based Comp.

$131M

Balance Sheet

Total Assets

$21.7B

Total Liabilities

$5.2B

Stockholders' Equity

$16.5B

Cash & Equivalents

$11.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.5B	$2.3B	+6.4%
Gross Profit	$2.2B	$2.0B	+5.9%
Operating Income	$1.0B	$1.1B	-7.9%
Net Income	$1.0B	$931M	+11.3%

Revenue Segments

TRIKAFTA/KAFTRIO

$2.3B92%

KALYDECO

$113M5%

ORKAMBI

$63M3%

SYMDEKO/SYMKEVI

$33M1%

Geographic Segments

UNITED STATES

$1.6B63%

Europe

$767M31%

Other, Non U.S.

$163M7%